Novel window on early human neurodevelopment via fetal exosomes in maternal blood

Goetzl, Laura; Darbinian, Nune; Goetzl, Edward J.

doi:10.1002/acn3.296

Cited by 37 publications

(70 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…98 Although these exosomal membrane-bound proteins are associated with pregnancy, they cannot be used as definitive markers of placenta-derived exosomes, due to their lack of placental specificity; therefore, placental ALP remains the marker of choice when isolating and identifying placenta-derived exosomes. [79][80][81]85,90,99,100 Even though it is known that exosomes contain mRNA and miRNA, which are key molecular mediators in translational and posttranscriptional modification, the exact composition of these exosomal constituents has not been elucidated in placenta-derived exosomes. Therefore, future studies should incorporate identification of novel nucleic acid sequences in placenta-derived exosomes in normal and PE pregnancies to enhance the specificity and sensitivity of these vesicles as biomarkers of PE.…”

mentioning

confidence: 99%

Placenta-derived exosomes: potential biomarkers of preeclampsia

Pillay¹,

Moodley²,

Moodley³

et al. 2017

IJN

111

View full text Add to dashboard Cite

Preeclampsia remains a leading cause of maternal and fetal mortality, due to ineffective treatment and diagnostic strategies, compounded by the lack of clarity on the etiology of the disorder. Although several clinical and biological markers of preeclampsia have been evaluated, they have proven to be ineffective in providing a definitive diagnosis during the various stages of the disorder. Exosomes have emerged as ideal biomarkers of pathological states, such as cancer, and have more recently gained interest in pregnancy-related complications, due to their role in cellular communication in normal and complicated pregnancies. This occurs as a result of the specific placenta-derived exosomal molecular cargo, which may be involved in normal pregnancy-associated immunological events, such as the maintenance of maternal–fetal tolerance. This review provides perspectives on placenta-derived exosomes as possible biomarkers for the diagnosis/prognosis of preeclampsia. Using keywords, online databases were searched to identify relevant publications to review the potential use of placenta-derived exosomes as biomarkers of preeclampsia.

show abstract

mentioning

confidence: 99%

Placenta-derived exosomes: potential biomarkers of preeclampsia

Pillay¹,

Moodley²,

Moodley³

et al. 2017

IJN

111

View full text Add to dashboard Cite

show abstract

“…[9][10][11][12] Currently, it is not possible to predict which opioid-exposed newborns will require pharmacotherapy for NAS. 22 Our published findings show that purified FCEs can be used to detect fetal CNS damage caused by in utero alcohol exposure, hypoxia and viral infection. Opioid dose is a poor predictor 13 ; some factors that have been associated with NAS severity include: cooccurring exposure to benzodiazepines, 14,15 anti-depressants, 16,17 marijuana use or heavy smoking, 18,19 as well as genetic factors.…”

Section: Introductionmentioning

confidence: 92%

“…22 Briefly, total ECVs were prepared from maternal plasma (EXOQ; System Biosciences, Inc., Mountainview, California). 22 Briefly, total ECVs were prepared from maternal plasma (EXOQ; System Biosciences, Inc., Mountainview, California).…”

Section: Preparation Of Fces and Synaptosomesmentioning

confidence: 99%

“…Between 47% and 81% of newborns with gestational methadone or buprenorphine exposure will require pharmacotherapy. 22,23 Thus FCEs could be a new tool to interrogate in vivo neurodevelopment involving elements of opioid signaling pathways, including proteins (mu-opioid receptor [μOR], cannabinoid receptors) and microRNAs (miRNAs). 20,21 None of these factors are sufficient to reliably predict NAS severity, and the mechanisms by which they impact NAS are not well understood.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Novel biomarkers to assess in utero effects of maternal opioid use: First steps toward understanding short‐ and long‐term neurodevelopmental sequelae

Goetzl

Thompson-Felix

Darbinian

et al. 2019

Genes Brain and Behavior

Self Cite

View full text Add to dashboard Cite

Maternal opioid use disorder is common, resulting in significant neonatal morbidity and cost. Currently, it is not possible to predict which opioid‐exposed newborns will require pharmacotherapy for neonatal abstinence syndrome. Further, little is known regarding the effects of maternal opioid use disorder on the developing human brain. We hypothesized that novel methodologies utilizing fetal central nervous system‐derived extracellular vesicles isolated from maternal blood can address these gaps in knowledge. Plasma from opioid users and controls between 9 and 21 weeks was precipitated and extracellular vesicles were isolated. Mu opioid and cannabinoid receptor levels were quantified. Label‐free proteomics studies and unbiased small RNA next generation sequencing was performed in paired fetal brain tissue. Maternal opioid use disorder increased mu opioid receptor protein levels in extracellular vesicles independent of opioid equivalent dose. Moreover, cannabinoid receptor levels in extracellular vesicles were upregulated with opioid exposure indicating cross talk with endocannabinoids. Maternal opioid use disorder was associated with significant changes in extracellular vesicle protein cargo and fetal brain micro RNA expression, especially in male fetuses. Many of the altered cargo molecules and micro RNAs identified are associated with adverse clinical neurodevelopmental outcomes. Our data suggest that assays relying on extracellular vesicles isolated from maternal blood extracellular vesicles may provide information regarding fetal response to opioids in the setting of maternal opioid use disorder. Prospective clinical studies are needed to evaluate the association between extracellular vesicle biomarkers, risk of neonatal abstinence syndrome and neurodevelopmental outcomes.

show abstract

“…In animal models, these cells have shown to produce the deficient proteins and make new muscle cells which fuse with the host fibers. Further, stem cell-derived exosomes which are small membrane vesicles and are responsible for inter-cellular communication, promote muscle regeneration by enhancing myogenesis and angiogenesis [74]. Physical Disabilities -Therapeutic Implications We conducted a study on 150 patients diagnosed with muscular dystrophy.…”

Section: Stem Cell Therapy In Duchenne Muscular Dystrophymentioning

confidence: 99%

Stem Cell Therapy in Pediatric Neurological Disabilities

Sharma¹,

Sane²,

Gokulchandran³

et al. 2017

Physical Disabilities - Therapeutic Implications

View full text Add to dashboard Cite

Pediatric neurological disorders represent a major part of the disabilities worldwide. In over 10 decades of research to find a cure for these disorders, medical science has not been able to repair the underlying brain injury. This chapter focuses on recent advances in the application of stem cells as a therapeutic tool for some of the common neurodevelopmental disorders (cerebral palsy, autism, intellectual disability and muscular dystrophy). The mechanism of action of stem cells in each disorder has been explained. A review of clinical data has been described giving a clear understanding of current status of stem cell therapy in these disorders. Various factors influencing the outcome of stem cell therapy such as different types of cells, different routes of administration and dosage and frequency of transplantation have also been discussed. Our experience of treating these disorders is exhibited in the form of our published data. Use of novel monitoring tools such as MRI MSK and PET-CT scan brain to track the changes occurring at cellular level after stem cell therapy are described. We also highlight the importance of a multidisciplinary approach of combining rehabilitation with stem cell therapy.

show abstract

Novel window on early human neurodevelopment via fetal exosomes in maternal blood

Cited by 37 publications

References 27 publications

Placenta-derived exosomes: potential biomarkers of preeclampsia

Placenta-derived exosomes: potential biomarkers of preeclampsia

Novel biomarkers to assess in utero effects of maternal opioid use: First steps toward understanding short‐ and long‐term neurodevelopmental sequelae

Stem Cell Therapy in Pediatric Neurological Disabilities

Contact Info

Product

Resources

About